Library

The purpose of the study is to study the emotional status (including Alexitimia, anxiety and depression) in patients with a brain infarction in the basin of the middle cerebral artery on the left in the late recovery period and the development of the method of correcting identified disorders.

Material and methods. The study was attended by 30 patients with a brain infarction in the basin of the middle cerebral artery on the left, the comparison group was 10 patients with chronic brain ischemia.

Results and conclusion. The data obtained demonstrate the dependence of the level of Alexitimia on the neurological deficit, gender, level of anxiety and depression. It was established that the development of brain infarction affects the level of Alexitimia. The presence of Alexitimia in patients with a brain infarction leads to a violation of adequate self -esteem of the physical and mental state, which can complicate the rehabilitation of such patients and requires correction - a combination of pharmacotherapy and psychotherapeutic effects.

Keywords: Alexitimia, brain heart attack, anxiety, depression.

Place of publication:
Journal of Neurology and Psychiatry, 3, 2014

Summary:
The purpose of the study is to analyze the effectiveness of the drug Mexidol in relation to the secondary prevention of ischemic stroke (AI). Material and methods. The results of the treatment of 3400 patients who were divided into 7 groups are analyzed: patients with cryptogenic AI, arterial hypertension, atrial fibrillation, metabolic syndrome, obstructive apnea/sleep hypnome, diabetes mellitus, vasculitis. Assessment of the effectiveness of therapy was based on the absence of repeated AI for 5 years of therapy. Results. Mexidol helps to reduce the frequency of repeated AI in both patients without concomitant pathological conditions, and in patients with arterial hypertension, obstructive apnea/sleep hypnome syndrome, vasculitis, diabetes mellitus, atrial fibrillation and metabolic syndrome. Conclusion. Further studies of the effectiveness of the use of Mexidol as a means of secondary prevention of AI are seemed very promising. Key words: stroke, secondary prevention, Mexidol.

Place of publication:
emergency medical care, 2, 2013

Summary:
114 patients with an isolated severe traumatic brain injury aged 18 to 55 years were examined and treated. The group I includes 61 surviving patient, in the II group-53 patients who died on the 3-and -15th day of the post-traumatic period. Patients of groups I and II received complex intensive therapy in accordance with the current protocols. Fifteen patients (subgroup I) were obtained as part of the complex therapy of Mexidol at a dose of 1200 mg/day for 7-10 days. Against the background of the use of Mexidol, the intensity of the processes of lipoperoxidation was reduced, the power of the cell antioxidant protection system remained at a sufficient level, and the earlier resolution of post -traumatic encephalopathy and the restoration of consciousness were observed. Against the background of treatment with Mexidol, a more favorable course of the early post-traumatic period, a decrease in complications (χ2 = 55.4; p <0.0001)-acute damage syndrome, DIC, acute cardiovascular failure and pneumonia are noted.

Place of publication:
Herald of intensive therapy, 2012, No. 3. Neuroreusterology

Summary:
annually in the world from a traumatic brain injury (ChMT), one and a half million people die, and 2.4 million become disabled. The frequency of the CCT in various regions of Ukraine is from 2.3 to 4.2% per year, and over the past 10 years has almost doubled. Missiles for a severe CCT is 40–70%, and in surviving patients, the full functional restoration of the central nervous system (central nervous system) is relatively rare.

Place of publication:
Pharmacate No. 19 - 2012

Summary:
In a study that included 34 patients, the effectiveness of Mexidol's preparation in the correction of astheno-vegetative disorders was studied in persons who have suffered a mild craniocre trauma (LCHMT) and a concussion of the brain. The use of Mexidol as part of the complex therapy of these disorders made it possible to improve the results of treatment compared to the control group of patients who did not receive Mexidol. It is noted that the prescription of the drug is preferably at an earlier date from the moment of injury. A distinct therapeutic effect was obtained when using Mexidol in a daily dose of 375 mg in a tablet form for 28-30 days in the acute and intermediate periods of the LCCMT. Side effects and complications during therapy were not observed in any group. It is concluded that Mexidol can be used in the complex treatment of LCHMTs, a concussion of the brain and the correction of the post -compliance syndrome.

Place of publication:
Journal of Neurology and Psychiatry, 6, 2012

Summary:
in the structure of cerebrovascular pathology, the stroke occupies a leading place as one of the main causes of mortality and primary disability of the population. In the treatment of a stroke, in the acute period, measures are the measures to correct the impaired functions of the body and maintain the viability of the nervous tissue. In the recovery period, drugs are used that have an activating effect on neurotrophic and reparative processes, and secondary prophylaxis of stroke is carried out. It is known that brain ischemia is a multifactor pathological process that includes a decrease in energy products with a violation of active vehicles through cell membranes, excessive accumulation of excitoxic excitation mediators in brain structures, an increase in ionized calcium in neurons, hyperproduction of free radicals and activation of oxidant stress. To correct these changes, preparations with antihyplance and antioxidant properties are traditionally used, which include Mexidol (2-ethyl-6-methyl-3-hydroxypyridine succinate). Mexidol improves the metabolism of nervous tissue, it is also known that it affects the rheological properties of blood, reduces platelet aggregation, and has a hypolipidemic effect.

Place of publication:
Medical alphabet. Emergency medicine 1/22

Summary:
Heddle-brain injury (ChMT) is one of the main reasons for the disability and death of the population. Moreover, mechanical damage to the central nervous system does not tend to decrease in the structure of diseases and injuries. According to WHO, the frequency of craniocre injury annually increases by 2%. In Russia, about 600,000 people receive a traumatic brain injury annually, of which about 50,000 die and the same number of disabled people (Gusev E.I., 2009). Mortality at a severe CMT, according to various estimates, ranges from 10 to 25%, and with the most severe forms reaches 65-70%. In the vast majority of victims (60%), a decrease in performance and disability (epileptic seizures, encephalopathy, paresis and paralysis, speech disorders and other neurological consequences) are observed as a result of injury.

Place of publication:
Bulletin of experimental biology and medicine, 2012, Appendix 1

Summary:
the use of Mexidol in a basic dose of 100 mg/day intramuscularly for 10 days is effective in the treatment of mild CITs, which is confirmed by positive neurological dynamics. In patients with a severe CCT, it is more advisable to use a 10-day treatment regimen with a mexidol at a dose of 200 mg/day intramuscularly with the subsequent transition to orally in a dose of 0.25 g 2 times a day for 4 weeks. Due to the good tolerance and the possibilities of intramuscular administration, Mexidol is an urgent drug in outpatient practice for the treatment and rehabilitation of patients of different age groups with the CCT.

Place of publication:
Stroke, 18, 2006

Summary:
patients with an ischemic stroke at the age of 45–85 years (51 people) entered the first 24 hours from the onset of the disease were included in the study. Mexidol was introduced at a dose of 300 mg/day 24 patients for 14 days from the beginning of the stroke. The placebo was introduced by 27 patients according to a similar scheme. A reliable advanced dynamics in the regression of neurological disorders on the NIH scale by the 14th day of the disease in the group of patients who received Mexol compared to the placebo group (p <0.05), as well as a reliable functional restoration (the dynamics of the clinical score on the Bartel scale at 21, were identified. -y day; p <0.05) in patients included in the study in the first 6 hours of the disease. The normalization of the functional activity of the brain was established in the treatment of Mexidol, including during acute pharmacological test. The complex of studies of the antioxidant system revealed an increase in the activity of its enzymes (superoxidsmutase, glutathioneperoxidase, glutathioneuctase) with the introduction of Mexidol compared to placebo. When analyzing the enzymes of the respiratory chain of mitochondria, an increase in the activity of succinate dehydrogenase was noted. Thus, a reliable clinical confirmation of the effectiveness of Mexidol was obtained in the acute period of ischemic stroke in the carotid system of an atherotrombotic or cardiembolic pathogenetic type, especially with an early (up to 6 hours) its appointment; The mechanisms of action of the drug (antihypoxic, antioxidant) in clinical conditions are clarified.

Summary:
intracranial hypertension syndrome (HDG) with distant consequences of closed cranial injury (CSMT) is manifested by organic and functional disorders of varying degrees of severity. The work uses a method for assessing the degree of ICG by measuring distances between the structures of the brain stem using magnetic resonance imaging. The calculation of the restriction index of the posterior cranial fossa made it possible to compare the data of 96 patients with the HRG, some of which received Mexidol, and 28 healthy volunteers. Observation was carried out during the year with a neurological examination in dynamics. A comparison of groups of patients with each other and with indicators of healthy individuals revealed reliable differences expressed to a lesser extent of the NCH after treatment with Mexidol. The study showed that the prolonged course use of Mexidol is an effective method of preventing episodes of increasing intracranial pressure in the remote period of mild ZchMT and can be recommended for wide use both in stationary and outpatient conditions.